Human IL-18 Antibody - Camoteskimab Biosimilar

Binding of anti-IL-18 mAb

Anti-human IL-18 - Camoteskimab biosimilar - CAS #2492472-82-7

Anti-hIL-18-hIgG1-FES is a biosimilar antibody of Camoteskimab, a human interleukin 18 (IL-18) antibody that inhibits IL-18 signaling. This monoclonal antibody (mAb) is currently under investigation for the treatment of atopic dermatitis and adult-onset Still's disease.

 More details

Anti-hIL-18-hIgG1-FES comprises the variable region of Camoteskimab and the effectorless IgG1 constant region of Camoteskimab harboring a triple mutation L242F/L243E/P339S (FES). 

This mAb can be used together with HEK-Blue™ IL-18 cells for screening and neutralization assays to inhibit IL-18 signaling induced by recombinant human IL-18 (see figure).

Key features

• Each lot is functionally tested and validated.
• The complete sequence of the antibody construct was verified.
• The absence of endotoxins is determined using the EndotoxDetect™ assay.

If you are interested in the corresponding isotype control Anti-β-Gal-hIgG1-FES mAb, please contact us. 

All InvivoGen products are for internal research use only, and not for human or veterinary use.

Figures

Dose-dependent inhibition of HEK-Blue™ IL-18 cells response using Camoteskimab biosimilar. Increasing concentrations of Anti-hIL-18-hIgG1-FES (0.1 ng/ml - 10 µg/ml) were incubated with recombinant human (h)IL-18 (30 pg/ml) for 1 h before the addition of HEK-Blue™ IL-18 cells. After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution. Data are shown in percentage of activity (%) (mean ± SEM).

Specifications

Application: Neutralization assay, ELISA

Isotype:   Human IgG1, kappa featuring triple mutation L242F/L243E/P339S

Recommended isotype control: Human IgG1

Target: Human IL-18

Species reactivity: Human

Clone: Camoteskimab,  AEVI-007, AVTX-007, CERC-007, MEDI 2338

Cas number: 2492472-82-7

Sterility: 0.2 µm filtration

Source: CHO cells 

Production: Animal-free

Purification: Protein A

Molecular weight: 146.4 kDa

Physical form: Lyophilized

Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative: Azide-free

Reconstitution buffer: Sterile water (not provided)

Purity: ≥ 95 %

Quality control: Each lot is functionally tested and validated

Contents

Anti-hIL-18-hIgG1-FES purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

• hil18-mab16: 100 µg
• hil18-mab16-03: 3 x 100 µg

 The product is shipped at room temperature.

 Upon receipt, store lyophilized antibody at -20 °C.

 Lyophilized product is stable for at least 1 year.

 Avoid repeated freeze-thaw cycles.

Details

Camoteskimab and IL-18 background

Camoteskimab is a fully human monoclonal antibody (mAb) designed to target interleukin 18 (IL-18) and block the IL-18 signaling [1]. Camoteskimab features a triple mutation L242F/L243E/P339S in its IgG1 constant region for low effector functions [2].

IL-18, formerly called interferon-γ (IFN-γ) inducing factor, is a pro-inflammatory cytokine that causes a variety of biological effects associated with infection, inflammation, and autoimmune processes [3]. It is a powerful inducer of type 1 responses mediated by activated NK, Th1, and CD8+ cytotoxic T cells [4]. 

Camoteskimab is under investigation for the treatment of Adult-Onset Still's Disease [1,4] and atopic dermatitis [NCT06436183].

References:

1. Bindoli S, et al., 2024. Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options. Drugs. 84(3):257-274.
2. https://go.drugbank.com/drugs/DB18876
3. Dinarello CA. et al., 1998. Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol. 63(6):658-64.
4. Baggio C, et al., 2023. IL-18 in Autoinflammatory Diseases: Focus on Adult Onset Still Disease and Macrophages Activation Syndrome. Int J Mol Sci.24(13):11125.
5. https://clinicaltrials.gov/study/NCT06436183